Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of
patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse …

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory
B-cell lymphomas and greatly improves disease outcomes. The impressive success has …

T-cell malignancy is a broad term used for a diverse group of disease subtypes representing
dysfunctional malignant T cells transformed at various stages of their clonal evolution …

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the
treatment of hematologic malignancies, with 9 CAR-T-cell products currently available …

MicroRNAs (miRNAs) characterized by small, noncoding RNAs have a fundamental role in
the regulation of gene expression at the post‐transcriptional level. Additionally, miRNAs …

Historical standard of care treatments of T-cell malignancies generally entailed the use of
cytotoxic and depleting approaches. These strategies are, however, poorly validated and …

Melatonin,(N-acetyl-5-methoxytryptamine) an indoleamine exerts multifaced effects and
regulates numerous cellular pathways and molecular targets associated with circadian …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute …

The SIN3 repressor complex and the NAD-dependent deacetylase SIRT3 control cell
growth, and development as well as malignant transformation. Even then, a little known …